Kalkine has a fully transformed New Avatar.

Rapid Therapeutic Science Lab inc

Financial Services US RTSL

0.006USD
-(-%)

Last update at 2026-03-09T13:30:00Z

Day Range

0.0060.006
LowHigh

52 Week Range

0.0010.008
LowHigh

Fundamentals

  • Previous Close 0.006
  • Market Cap0.13M
  • Volume0
  • P/E Ratio0.70
  • Dividend Yield-%
  • EBITDA-0.44109M
  • Revenue TTM0.00006M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00033M
  • Diluted EPS TTM0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-12-31 2022-03-31 2021-12-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-12-31 2022-03-31 2021-12-31 2021-03-31
Income before tax -1.79473M -1.79473M -2.86788M -2.86788M -
Minority interest - - - - -
Net income -1.69380M -1.69380M -4.19732M -4.19732M -
Selling general administrative 1.24M 1.24M 2.11M 2.11M -
Selling and marketing expenses - - - - -
Gross profit 0.00000M 0.00000M 0.00033M 0.00033M -
Reconciled depreciation 0.02M 0.02M 0.06M 0.06M -
Ebit -1.26333M -1.26333M -2.17029M -2.17029M -2.24137M
Ebitda -1.23936M -1.23936M -2.11444M -2.11444M -
Depreciation and amortization 0.02M 0.02M 0.06M 0.06M -
Non operating income net other - - - - -
Operating income -1.26333M -1.26333M -2.17029M -2.17029M -
Other operating expenses 1.26M 1.26M 2.17M 2.17M -
Interest expense 1.90M 1.90M 1.33M 1.33M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M -
Interest income - - - - -
Net interest income -1.89565M -1.89565M -1.32944M -1.32944M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.10092M -0.10092M 1.33M 1.33M -
Total revenue 0.00000M 0.00000M 0.00053M 0.00053M -
Total operating expenses 1.26M 1.26M 2.17M 2.17M -
Cost of revenue 0.00000M 0.00000M 0.00020M 0.00020M -
Total other income expense net -0.53139M -0.53139M -0.69759M -0.69759M -
Discontinued operations - - - - -
Net income from continuing ops -1.79473M -1.79473M -2.86788M -2.86788M -
Net income applicable to common shares - - -2.86788M -2.86788M -2.36327M
Preferred stock and other adjustments - - - - -
Breakdown 2023-03-31 2022-12-31 2022-03-31 2021-12-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-12-31 2022-03-31 2021-12-31 2021-03-31
Total assets 2.25M 2.25M 2.20M 2.20M -
Intangible assets 0.17M 0.17M 0.17M 0.17M -
Earning assets - - - - -
Other current assets 0.06M 0.06M 0.05M 0.05M -
Total liab 5.40M 5.40M 3.58M 3.58M -
Total stockholder equity -3.14148M -3.14148M -1.38176M -1.38176M -
Deferred long term liab - - - - -
Other current liab 0.67M -0.21743M 1.09M 0.62M 0.04M
Common stock 0.00776M 0.00776M 0.19M 0.19M 0.18M
Capital stock 0.00776M 0.00776M 0.19M 0.19M -
Retained earnings -10.31615M -10.31615M -8.52142M -8.52142M -5.65354M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash -0.37874M -0.37874M 0.19M 0.19M -
Cash and equivalents - - - - -
Total current liabilities 4.97M 4.97M 3.05M 3.05M 1.21M
Current deferred revenue - - 0.05M 0.05M -
Net debt 4.21M 4.21M 1.79M 1.79M -
Short term debt 3.40M 3.40M 1.46M 1.46M -
Short long term debt 3.30M 3.30M 1.38M 1.38M -
Short long term debt total 3.83M 3.83M 1.99M 1.99M -
Other stockholder equity 7.17M 7.17M 6.95M 6.95M -
Property plant equipment - - 1.61M 1.61M 0.60M
Total current assets 0.23M 0.23M 0.42M 0.42M 0.69M
Long term investments - - - - -
Net tangible assets - - -1.55183M -1.55183M -0.23870M
Short term investments - - - - -
Net receivables 0.38M 0.38M - - -
Long term debt 0.15M 0.15M 0.15M 0.15M -
Inventory 0.18M 0.18M 0.18M 0.18M 0.19M
Accounts payable 0.89M 0.89M 0.47M 0.47M 0.11M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.17M 0.17M - - -
Deferred long term asset charges - - - - -
Non current assets total 2.02M 2.02M 1.78M 1.78M -
Capital lease obligations 0.38M 0.38M 0.45M 0.45M -
Long term debt total - - - - -
Breakdown 2023-03-31 2022-12-31 2022-03-31 2021-12-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-12-31 2022-03-31 2021-12-31 2021-03-31
Investments -0.03916M -0.03916M -0.29253M -0.29253M -
Change to liabilities - - 0.08M 0.08M 0.03M
Total cashflows from investing activities - - -0.29253M -0.29253M -0.10674M
Net borrowings - - 1.61M 1.61M 0.27M
Total cash from financing activities 1.00M 1.00M 2.19M 2.19M 2.36M
Change to operating activities - - -0.02706M -0.02706M 0.07M
Net income -1.79473M -1.79473M -2.86788M -2.86788M -2.36327M
Change in cash -0.19248M -0.19248M -0.30666M -0.30666M 0.37M
Begin period cash flow 0.19M 0.19M 0.50M 0.50M 0.14M
End period cash flow 0.00000M 0.00000M 0.19M 0.19M 0.50M
Total cash from operating activities -1.15171M -1.15171M -2.20913M -2.20913M -1.87875M
Issuance of capital stock 0.00000M 0.00000M 0.58M 0.58M -
Depreciation 0.02M 0.02M 0.06M 0.06M 0.11M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - 0.01M 0.01M -0.18680M
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 1.29M 1.29M 1.91M -0.29253M -0.09000M
Change to netincome - - -0.59059M -0.59059M 0.46M
Capital expenditures 0.04M 0.04M 0.29M 0.29M 0.11M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.20M 0.20M 0.07M 0.07M -
Stock based compensation 0.02M 0.02M 0.02M 0.02M -
Other non cash items 0.40M 0.40M 1.15M 1.15M -
Free cash flow -1.19086M -1.19086M -2.50166M -2.50166M -

Peer Comparison

Sector: Financial Services Industry: Shell Companies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RTSL
Rapid Therapeutic Science Lab inc
- -% 0.006 0.70 - 16784.09 136.70 79847.58 5.84
AGLY
Agiliti Inc
- -% 0.02 - - 487.42 4.19 1814.52 -18211.8716
SVMB
SavMobi Technology Inc.
- -% 1.66 - - 239.23 - 363.28 -319.6012
PBAJ
Petro Usa Inc
- -% 0.0005 - - - - -9042.9978
ANSC
Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares
0.02 0.18% 11.26 38.67 - - 1.31

Reports Covered

Stock Research & News

Profile

Rapid Therapeutic Science Laboratories, Inc. operates as a biotech company, provides natural based relief through aerosol delivery systems for non-psychoactive cannabinoids. The company was formerly known as Holly Brothers Pictures, Inc. and changed its name to Rapid Therapeutic Science Laboratories, Inc. in January 2020. Rapid Therapeutic Science Laboratories, Inc. was incorporated in 2013 and is based in Dallas, Texas.

Rapid Therapeutic Science Lab inc

5580 Peterson Lane, Dallas, TX, United States, 75201

Key Executives

Name Title Year Born
Mr. Donal R. Schmidt Jr. Pres, CEO & Chairman 1961
Mr. D. Hughes Watler Jr. CFO & Director 1949
Dr. Duane Drinkwine Ph.D. Chief Science Officer NA
Mr. Ryan C. Johnson VP of Marketing 1975
Mr. Frank Gill Chief Isolate Laboratory Technician NA
Mr. Sean Paul Berrier Sr. VP NA
Mr. Donal R. Schmidt Jr. President, CEO & Chairman 1961
Dr. Duane C. Drinkwine Ph.D. Chief Science Officer NA
Mr. Ryan C. Johnson Vice President of Marketing 1975
Mr. Sean Paul Berrier Senior Vice President NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.